文献速递神经康复

地面机器人外骨骼与常规治疗在住院卒中康复中的比较:务实性多中心实施项目结果

Overground robotic exoskeleton vs conventional therapy in inpatient stroke rehabilitation: results from a pragmatic, multicentre implementation programme.
PubMed 文献 · J Neuroeng Rehabil · 2025-01-06

该研究分析IMOVE多中心实施项目中149例住院卒中患者(105例接受地面机器人外骨骼,44例接受常规治疗),两组运动结局均显著改善且组间无显著差异;基线FAC 1者外骨骼组FIM运动亚分改善显著优于对照组,基线FAC 0和1者外骨骼组每次治疗步行距离约为对照组三倍。

要点

  • 两组运动结局均显著改善,组间无显著差异。
  • 基线FAC 1者外骨骼组FIM运动亚分改善显著优于对照组。
  • 基线FAC 0和1者外骨骼组每次治疗步行距离约为对照组三倍。

核心结论

  • 在务实性设置中,地面机器人外骨骼用于步态训练可使步行能力较低的患者在治疗期间行走更远距离。
  • 需要持续辅助行走(FAC 1)的患者接受外骨骼训练后FIM运动亚分改善显著优于常规治疗,提示该组可能获益。

研究设计与样本

  • 分析IMOVE多中心临床实施项目的前瞻性收集数据,参与者可选择12次地面机器人外骨骼或常规治疗。
  • 纳入标准为原发诊断为卒中(缺血性或出血性,首发或复发)、卒中发病9个月内且干预期间住院,并符合IMOVE一般纳入和排除标准。
  • 共纳入149例参与者,其中地面机器人外骨骼组105例,对照组44例。

主要发现

  • 两组运动结局均显著改善,组间无显著差异。
  • 基线FAC 1者外骨骼组FIM运动亚分改善显著大于对照组(平均差8.4,95%CI 0.65-16.07,ηp2=0.136,p=0.034)。
  • 基线FAC 0者外骨骼组每次治疗平均步行距离为121.5(SD 31.1)m,对照组为35.0(SD 41.0)m(95%CI 62.2-110.9,d=2.54,p<0.001)。
  • 基线FAC 1者外骨骼组每次治疗平均步行距离为145.8(SD 31.6)m,对照组为52.2(SD 42.5)m(95%CI 61.8-125.2,d=2.71,p<0.001)。
  • 基线FAC 2至3者两组每次治疗平均步行距离差异无统计学意义(162.9 [SD 29.2]m vs 134.2 [SD 87.5]m,95%CI -22.2至79.7,d=0.41,p=0.252)。

关键数值与推荐

  • 结局指标包括功能性步行分类(FAC)、Rivermead移动指数(RMI)、功能独立性评定(FIM)和临床结局变量量表(COVS),在12次治疗前后即刻测量,并记录每次治疗平均步行距离。

临床怎么用

  • 对于住院卒中后步行能力较低(FAC 0至1)的患者,可考虑使用地面机器人外骨骼进行步态训练以增加治疗期间步行距离。
  • 对于需要持续辅助行走(FAC 1)的患者,地面机器人外骨骼可能带来FIM运动亚分额外改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the reported efficacy of overground robotic exoskeleton (ORE) for rehabilitation of mobility post-stroke, its effectiveness in real-world practice is still debated. We analysed prospectively collected data from Improving Mobility Via Exoskeleton (IMOVE), a multicentre clinical implementation programme of ORE enrolling participants with various neurological conditions and were given options to choose between 12 sessions of ORE or conventional therapy (control). METHODS: This is analysis of participants under IMOVE who fulfilled the following criteria (i) primary diagnosis was stroke (ischemic, hemorrhagic; first or recurrent), (ii) onset of stroke was within 9 months and (iii) the intervention was during inpatient stay. They should also fulfill the general IMOVE inclusion and exclusion criteria which were resembling general clinical and manufacturing criteria of ORE. Outcome measures included Functional Ambulatory Category (FAC), Rivermead Mobility Index (RMI), Functional Independence Measure (FIM) and Clinical Outcome Variable Scale (COVS), measured immediately before and after the 12 sessions of therapy, and mean distance walked per session. RESULTS: Of 149 participants (105 OREs and 44 controls), both groups improved significantly in motor outcomes with no significant between-group differences. Participants with baseline FAC 1 had significantly greater improvement in motor sub-score of FIM (FIM-motor) compared to controls (mean difference 8.4, 95% CI 0.65-16.07, ηp2 = 0.136, p = 0.034). The mean distance walked per session for ORE group was almost three times that of control for those with baseline FAC 0 (121.5 [SD 31.1]m vs 35.0 [SD 41.0]m, 95% CI 62.2-110.9, d = 2.54 p < 0.001) and FAC 1 (145.8 [SD 31.6]m vs 52.2 [SD 42.5]m, 95% CI 61.8-125.2, d = 2.71, p < 0.001). The difference was not observed for FAC 2 to 3 (162.9 [SD 29.2]m vs 134.2 [SD 87.5]m, 95% CI -22.2 to 79.7, d = 0.41, p = 0.252). CONCLUSION: In a pragmatic setting, use of ORE for gait training enabled patients with lower ambulatory capacity to walk longer distances during therapy sessions. Patients who required continuous assistance during ambulation (FAC 1) had significantly better gains in FIM-motor compared to conventional therapy, suggesting possible benefit of ORE for this group. TRIAL REGISTRATION: The trial was registered with clinicaltrials.gov (NCT05659121) on April 14, 2022.

来源:J Neuroeng Rehabil,查看原文。版权归原作者所有。

引用

  1. Tam PK, Tang N, Kamsani NSB, et al. Overground robotic exoskeleton vs conventional therapy in inpatient stroke rehabilitation: results from a pragmatic, multicentre implementation programme. J Neuroeng Rehabil. 2025. PMID: 39762953. doi:10.1186/s12984-024-01536-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。